Showing 2151-2160 of 10548 results for "".
Clinical Questions About Isotretinoin and More
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/clinical-questions-about-isotretinoin-and-more/54661/Lawrence Eichenfield, MD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.Updates on Psoriasis Biologics
https://practicaldermatology.com/programs/practical-dermatology/updates-on-psoriasis-biologics/35894/Jashin J. Wu, MD, discusses biologics for psoriasis, including a meta-analyses of best biologics for different types of the condition, at Music City SCALE 2025.Cutaneous Toxicities in Graft-versus-host Disease
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/cutaneous-toxicities-in-graft-versus-host-disease/33013/Meghan Heberton, MD, an assistant professor of dermatology at UT Southwestern Medical Center, talks about her presentation at Masterclasses in Dermatology on the latest updates on cutaneous toxicities in Graft-versus-host (GvHD) disease.Noah Worcester 2024: Dr. Cohen on Lasers
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-cohen-lasers/24578/Joel L. Cohen, MD, FAAD, summarizes his lecture on laser resurfacing and perioral rejuvenation at the 2024 Noah Worcester Dermatological Society meeting.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iHair Care Trends You Need to Know
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-you-need-to-know/19976/People are sharing more than their latest dance moves on TikTok. Many—with no background in science—are dispensing hair care advice, some of which could even be dangerous. Learn which trends you should know about in order to educate your patients about what really works versus what could do more harEye Opener
https://practicaldermatology.com/programs/practical-dermatology/eye-opener/19918/From each individual's implicit bias to the systemic bias that influences the tools of research and clinical practice, innumerable factors go into every patient encounter. Only individuals who are open to recognizing and confronting bias can overcome it. Panelists share their personal perspectives oPatient Assessment: A Key to AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/patient-assessment-a-key-to-ad-care/19889/What is the Quality of Care in Atopic Dermatitis initiative, and why is it important? Dr. Stephan Weidinger shares his thoughts on the importance of this "impressive" program and offers suggestions to improve the assessment and care of patents with eczema.